Jan Astermark
81 – 90 of 191
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2014
-
Mark
Clinically relevant non-neutralizing anti-FVIII antibodies in a hemophiliac
- Contribution to journal › Letter
- 2013
-
Mark
The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.
- Contribution to journal › Article
-
Mark
Long-term anti-FVIII antibody response in Bethesda-negative haemophilia A patients receiving continuous replacement therapy.
- Contribution to journal › Article
-
Mark
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A
- Contribution to journal › Article
-
Mark
Incidence, mortality rates and causes of deaths in haemophilia patients in Sweden.
- Contribution to journal › Article
-
Mark
F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
- Contribution to journal › Article
- 2012
-
Mark
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis
- Contribution to journal › Scientific review
-
Mark
Exposure to factor VIII and prediction of inhibitor development: exposure days vs. danger days, or both?
- Contribution to journal › Letter
-
Mark
Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy.
- Contribution to journal › Article
-
Mark
The Arosenius Fund.
- Contribution to journal › Article